



**meetings  
in a box**

ROAD TO



**ASCO GI 2025**

A cura di Alessandro Pastorino, Genova

## ESOPHAGUS AND STOMACH

**INNOVATION** Chemo vs chemo + Trast vs chemo + Trast + Pert in HER2 locally advanced gastric cancer (LBA331)

## HEPATOBIILIARY

**ACCELERATE** Adjuvant chemo vs chemoradiation in gallbladder cancer (Abs 519)

**CAP-ACE** TACE + Camrelizumab and Apatinib vs TACE in intermediate stage HCC (LBA522)

**CM 9DW** Nivo Ipi vs Sorafenib/Lenvatinib in 1L HCC (Abs 520)

**RACB** Resection after Atezo Bev in initially unresectable HCC (Abs 521)

## COLORECTAL

**BREAKWATER** Chemo + Encorafenib Cetuximab vs chemo in 1L BRAFmut CRC (Abs 16)

**CM 9HW** Ipi Nivo vs Nivo in 1L MSI-H/dMMR CRC (LBA143)

**BOT BAL** Botensilimab Balstilimab in refractory MSS/pMMR without liver metastases (Abs 23)

**RESET-C** Single cycle neoadjuvant Pembrolizumab in stage I-III dMMR CRC (Abs 19)

**MRD detection** BESPOKE (Abs 15) and SWOG80702 (LBA14)